Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A third dipetdyl peptidase-4 (dpp-4) inhibitor has been approved by the FDA. Linagliptin follows sitagliptin and saxagliptin to the market. It is marketed by Boehringer Ingelheim as Tradjenta.

Linagliptin Tablets (Tradjenta™)